NASDAQ:ADPT Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis $4.27 -0.08 (-1.84%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$4.21▼$4.4650-Day Range$3.37▼$4.9352-Week Range$2.28▼$6.86Volume506,596 shsAverage Volume1.50 million shsMarket Capitalization$629.26 millionP/E RatioN/ADividend YieldN/APrice Target$6.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Adaptive Biotechnologies alerts: Email Address Adaptive Biotechnologies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside49.9% Upside$6.40 Price TargetShort InterestHealthy6.56% of Shares Sold ShortDividend StrengthN/ASustainability-0.79Upright™ Environmental ScoreNews Sentiment0.65Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.19) to ($1.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.79 out of 5 starsMedical Sector204th out of 910 stocksBiological Products, Except Diagnostic Industry28th out of 155 stocks 3.3 Analyst's Opinion Consensus RatingAdaptive Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAdaptive Biotechnologies has only been the subject of 1 research reports in the past 90 days.Read more about Adaptive Biotechnologies' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.56% of the outstanding shares of Adaptive Biotechnologies have been sold short.Short Interest Ratio / Days to CoverAdaptive Biotechnologies has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Adaptive Biotechnologies has recently decreased by 11.78%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdaptive Biotechnologies does not currently pay a dividend.Dividend GrowthAdaptive Biotechnologies does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAdaptive Biotechnologies has received a 61.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Basic medical research services", "Scientific databases", and "Medical laboratory automation systems" products. See details.Environmental SustainabilityThe Environmental Impact score for Adaptive Biotechnologies is -0.79. Previous Next 1.5 News and Social Media Coverage News SentimentAdaptive Biotechnologies has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Adaptive Biotechnologies this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for ADPT on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Adaptive Biotechnologies to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adaptive Biotechnologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.20% of the stock of Adaptive Biotechnologies is held by insiders.Percentage Held by Institutions99.17% of the stock of Adaptive Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Adaptive Biotechnologies' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($1.19) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptive Biotechnologies is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptive Biotechnologies is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptive Biotechnologies has a P/B Ratio of 2.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Adaptive Biotechnologies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.So go here now to read my new report The Big AI Die-Up… while you still can. About Adaptive Biotechnologies Stock (NASDAQ:ADPT)Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Read More ADPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADPT Stock News HeadlinesSeptember 3, 2024 | americanbankingnews.comShort Interest in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Declines By 11.8%August 30, 2024 | americanbankingnews.comBrokerages Set Adaptive Biotechnologies Co. (NASDAQ:ADPT) Price Target at $6.40September 7, 2024 | Behind the Markets (Ad)The $15 "Insider Secret" That Could Save Your RetirementWhat if I told you there's a $15 stock that a billionaire insider just poured $47 MILLION into? That's right. You can grab shares of this potential retirement-maker for less than you'd pay for lunch.August 29, 2024 | globenewswire.comAdaptive Announces IVDR Certification for clonoSEQ® in European UnionAugust 22, 2024 | globenewswire.comAdaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 22, 2024 | msn.comMicrosoft Tips $30 Xbox Adaptive Joystick for Players With Limited MobilityAugust 22, 2024 | msn.comMicrosoft’s new Adaptive Joystick for Xbox is designed for players with limited mobilityAugust 18, 2024 | finance.yahoo.comADPT Sep 2024 7.500 call (ADPT240920C00007500)September 7, 2024 | Behind the Markets (Ad)The $15 "Insider Secret" That Could Save Your RetirementWhat if I told you there's a $15 stock that a billionaire insider just poured $47 MILLION into? That's right. You can grab shares of this potential retirement-maker for less than you'd pay for lunch.August 16, 2024 | yahoo.com'Means the world': West Herr, Scott Bieler donate new handcycles to Greater Buffalo Adaptive SportsAugust 4, 2024 | msn.comCO Adaptive overhauls Queens home to meet Passive House standardsAugust 4, 2024 | techcrunch.comChad RobinsAugust 3, 2024 | msn.comAdaptive Biotechnologies Corporation (NASDAQ:ADPT) Q2 2024 Earnings Call TranscriptAugust 2, 2024 | seekingalpha.comAdaptive Biotechnologies Corporation 2024 Q2 - Results - Earnings Call PresentationAugust 1, 2024 | markets.businessinsider.comAdaptive Biotechnologies Q2 Loss NarrowsAugust 1, 2024 | globenewswire.comAdaptive Biotechnologies Reports Second Quarter 2024 Financial ResultsJuly 26, 2024 | theglobeandmail.comClosing Bell: GX Resolve Adaptive Asset Allctn Corp Cls ETF down on Thursday (HRAA)July 26, 2024 | finance.yahoo.comFidus Awarded AMD Adaptive Compute Partner of the YearSee More Headlines Receive ADPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ADPT CUSIPN/A CIK1478320 Webwww.constructionpartners.net Phone(206) 659-0067Fax206-659-0667Employees709Year Founded2009Price Target and Rating Average Stock Price Target$6.40 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+49.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-225,250,000.00 Net Margins-126.49% Pretax Margin-126.55% Return on Equity-60.99% Return on Assets-27.99% Debt Debt-to-Equity RatioN/A Current Ratio3.99 Quick Ratio3.84 Sales & Book Value Annual Sales$168.77 million Price / Sales3.73 Cash FlowN/A Price / Cash FlowN/A Book Value$1.64 per share Price / Book2.60Miscellaneous Outstanding Shares147,368,000Free Float138,231,000Market Cap$629.26 million OptionableOptionable Beta1.35 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Chad M. Robins M.B.A. (Age 49)Co-Founder, CEO & Chairman Comp: $1MMs. Julie Rubinstein (Age 52)President & COO Comp: $721.04kDr. Harlan S. Robins Ph.D. (Age 51)Co-Founder & Chief Scientific Officer Comp: $711.09kDr. Sharon Benzeno Ph.D. (Age 50)Chief Commercial Officer of Immune Medicine Comp: $630.72kMr. Christopher Carlson Ph.D.FounderMr. Kyle Piskel (Age 40)VP, CFO & Principal Accounting Officer Comp: $375.9kKarina CalzadillaVice President of Investor RelationsMs. Stacy L. Taylor (Age 64)Senior VP, General Counsel & Corporate Secretary Mr. Francis T. Lo (Age 43)Chief People Officer Ms. Susan Bobulsky (Age 43)Chief Commercial Officer of MRD More ExecutivesKey CompetitorsFluidigmNASDAQ:FLDMKodiak SciencesNASDAQ:KODImmunityBioNASDAQ:IBRXVericelNASDAQ:VCELTwist BioscienceNASDAQ:TWSTView All CompetitorsInsiders & InstitutionsB. Riley Wealth Advisors Inc.Bought 13,500 shares on 8/19/2024Ownership: 0.009%Algert Global LLCSold 103,163 shares on 8/16/2024Ownership: 0.044%Deerfield Management Company L.P. Series CBought 57,554 shares on 8/15/2024Ownership: 0.083%The Manufacturers Life Insurance Company Bought 2,710 shares on 8/15/2024Ownership: 0.033%Susquehanna Fundamental Investments LLCBought 12,180 shares on 8/15/2024Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions ADPT Stock Analysis - Frequently Asked Questions How have ADPT shares performed this year? Adaptive Biotechnologies' stock was trading at $4.90 at the start of the year. Since then, ADPT stock has decreased by 12.9% and is now trading at $4.27. View the best growth stocks for 2024 here. How were Adaptive Biotechnologies' earnings last quarter? Adaptive Biotechnologies Co. (NASDAQ:ADPT) issued its quarterly earnings data on Thursday, August, 1st. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.02. The firm's revenue was down 11.7% on a year-over-year basis. What is Chad Robins' approval rating as Adaptive Biotechnologies' CEO? 51 employees have rated Adaptive Biotechnologies Chief Executive Officer Chad Robins on Glassdoor.com. Chad Robins has an approval rating of 92% among the company's employees. This puts Chad Robins in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. When did Adaptive Biotechnologies IPO? Adaptive Biotechnologies (ADPT) raised $200 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 12,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers. Who are Adaptive Biotechnologies' major shareholders? Top institutional shareholders of Adaptive Biotechnologies include Rubric Capital Management LP (9.50%), ARK Investment Management LLC (7.74%), Millennium Management LLC (6.29%) and Sumitomo Mitsui Trust Holdings Inc. (4.68%). Insiders that own company stock include Chad M Robins, Tycho Peterson, Julie Rubinstein, Nitin Sood, R Mark Adams, Stacy L Taylor, Kyle Piskel, Michelle Renee Griffin, Lance Baldo, Harlan S Robins and Chad M Cohen. View institutional ownership trends. How do I buy shares of Adaptive Biotechnologies? Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Adaptive Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptive Biotechnologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), QUALCOMM (QCOM), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), CrowdStrike (CRWD) and Home Depot (HD). This page (NASDAQ:ADPT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptive Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.